Last Updated on June 9, 2023 by The Health Master
Brentford: GSK will stop selling its blood cancer drug Blenrep in the United States, it said, representing the latest in a series of setbacks for the British drugmaker’s oncology business.
The company said this month that Blenrep failed to meet the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the U.S. Food and Drug Administration (USFDA).
GSK said it has begun the process of withdrawing Blenrep’s marketing authorization in the country but will continue trial programs for the drug, adding that some patients will have the option to enroll for continued access to the treatment.
“We will continue the DREAMM clinical trial program and work with the USFDA on a path forward for this important treatment option for patients with multiple myeloma,” GSK Chief Medical Officer Sabine Luik said in a statement.
GSK said access to Blenrep in other countries where it is marketed is unaffected, including across the European Union.
The company is still discussing the latest clinical data with EU health authorities, a GSK official said.
The drug was given speedy approval by the USFDA in 2020 and approved for patients with relapsed or refractory multiple myeloma who received at least four previous therapies.
Last year, the drug earned 89 million pounds ($105 million) in global sales, with roughly two-thirds of that coming from the United States.
Oncology is a key area of focus for GSK as a standalone prescription medicine and vaccine business, but the company suffered another blow this month after it had to limit the use of its ovarian cancer drug Zejula in the United States.
Blenrep belongs to a category of treatments called antibody-drug conjugates, which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals.
USFDA gives nod for Nifedipine ER tablets
NPPA: No bar on taking corrective measures if some error occurs
RIICO to develop Medical Devices Park
USFDA gives nod for Amphotericin B Liposome Injection
USFDA issues Form 483 with 10 observations to Aurobindo Pharma
USFDA gives approval for Potassium-deficiency drug
Govt starts drive against misuse of Antibiotics
Bar code or QR code for 300 brands: Govt notifies these drugs under Schedule H2
USFDA gives EIR to Aurobindo Pharma for its AP facility
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
